Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists

被引：17
|
作者：
Mann, Johannes F. E. [1 ,2 ]
Muskiet, Marcel H. A. [3 ]
机构：
[1] KfH Kidney Ctr, 15 Isoldenst, D-80804 Munich, Germany
[2] Friedrich Alexander Univ, Univ Hosp, Dept Nephrol & Hypertens, Erlangen, Germany
[3] Vrije Univ, Amsterdam Univ, Med Ctr, Dept Internal Med,Diabet Ctr, Amsterdam, Netherlands
来源：
KIDNEY INTERNATIONAL | 2021年 / 99卷 / 02期
关键词：
RENAL OUTCOMES; CARDIOVASCULAR OUTCOMES; LIRAGLUTIDE;
D O I：
10.1016/j.kint.2020.08.036
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：314 / 318
页数：5
相关论文
共 50 条
  • [21] Incretin-based antidiabetics: GLP-1 mimetics and DPP-IV inhibitors
    Gallwitz, B.
    DIABETOLOGIE UND STOFFWECHSEL, 2008, 3 (04) : 234 - +
  • [22] Global View on Safety and Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors
    Timofte, L.
    Stratmann, B.
    Bojita, M. T.
    Quester, W.
    Tschoepe, D.
    DIABETES STOFFWECHSEL UND HERZ, 2015, 24 (01): : 19 - 27
  • [23] SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
    El Mouhayyar, Christopher
    Riachy, Ruba
    Khalil, Abir Bou
    Eid, Asaad
    Azar, Sami
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2020, 2020
  • [24] DPP-4 inhibitors and GLP-1 agonists in type 2 diabetes - early assessment of cardiovascular safety in a nationwide setting
    Mogensen, U. M.
    Andersson, C.
    Fosbol, E. L.
    Schramm, T. K.
    Vaag, A.
    Scheller, N. M.
    Pedersen, C. T.
    Gislason, G.
    Kober, L.
    EUROPEAN HEART JOURNAL, 2013, 34 : 1111 - 1111
  • [25] Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes
    Kutz, Alexander
    Kim, Dae Hyun
    Wexler, Deborah J.
    Liu, Jun
    Schneeweiss, Sebastian
    Glynn, Robert J.
    Patorno, Elisabetta
    DIABETES CARE, 2023, 46 (11) : 2004 - 2014
  • [26] The Pharmacologic Basis for Clinical Differences Among GLP-1 Receptor Agonists and DPP-4 Inhibitors
    Morales, Javier
    POSTGRADUATE MEDICINE, 2011, 123 (06) : 189 - 201
  • [27] Sulfonylurea Prescribing Patterns After the Introduction of DPP-4 Inhibitors and GLP-1 Receptor Agonists
    Payk, Stephanie L.
    Drew, Richard H.
    Smith, Jennifer D.
    Jiroutek, Michael R.
    Holland, Melissa A.
    CLINICAL THERAPEUTICS, 2015, 37 (07) : 1477 - 1482
  • [28] Review: In type 2 diabetes, SGLT-2 inhibitors or GLP-1 agonists reduce mortality vs control or DPP-4 inhibitors
    Egan, Aoife M.
    Montori, Victor M.
    ANNALS OF INTERNAL MEDICINE, 2018, 169 (02) : JC2 - JC2
  • [29] Incretin mimetic drugs (GLP-1 receptor agonists and DPP-4 inhibitors) and associated adverse events and renal outcomes: A Pharmacoepidemiologic analysis using the FAERS database
    Alshannaq, Hamza
    Guo, Jeff Jianfei
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 571 - 571
  • [30] Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review
    Bihan, Helene
    Ng, Winda L.
    Magliano, Dianna J.
    Shaw, Jonathan E.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 121 : 27 - 34
12345